Funder: The Honorable Tina Brozman Foundation (Tina's Wish)
Due Dates: September 15, 2026, 1 PM ET (LOI) | October 26, 2026 (Full application invitations) | December 15, 2026 (Full application) | March 29, 2027 (Finalist presentations, tentative) | April 5, 2027 (Award notification) | July 1, 2027 (Funding starts)
Funding Amounts: Up to $1,000,000 in total costs over two years, capped at $500,000 annually
Summary: Funding and expert advisory support help investigator teams advance validated ovarian cancer biomarkers toward clinical translation.
Key Information: Full applications are by invitation only; projects must have completed EDRN Phase 2 or reached Phase 3 or 4.
Description
Tina’s Wish’s Acceleration to Clinic (A2C) Grant combines research funding with expert advisory resources to advance ovarian cancer-specific biomarkers toward clinical use. The program uses the National Cancer Institute’s Early Detection Research Network (EDRN) five-phase biomarker development framework to assess readiness. It supports rigorous, milestone-driven validation projects focused on early detection or interception, including screening tests and multi-analyte or composite signatures using protein, genomic, epigenomic, metabolomic, or imaging-based approaches.
A2C aims to strengthen translational decisions, reduce development risks, and position projects for clinical advancement and external funding. The program supports investigators designing investigator-initiated clinical trials during the grant period, with projects expected to progress toward clinical translation within one year after the grant ends.
